Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan, a blood pressure treatment.
in chemistry from Boston University in 1977, and a Ph.D. in organic chemistry working with Amos B. Smith at the University of Pennsylvania in 1982.
[2][3] Wexler started her career at DuPont in 1982, rising to Executive Director in 1998.
She then joined Bristol-Myers Squibb as an Executive Director in 2001, moving eventually to New Jersey to head their cardiovascular research unit.
[2] She has worked on targets involved in apoptosis, inflammation, obesity, and coagulation.